Amido compounds and their use as pharmaceuticals

Details Amido compounds and their use as pharmaceuticals Amido compounds and their use as pharmaceuticals

2007-12-04

2007-12-04

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S380000, C514S383000, C514S409000, C548S265800, C548S247000, C548S190000, C548S525000, C546S015000, C544S230000, C544S070000

Reexamination Certificate

active

11122309

ABSTRACT:
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

REFERENCES:
patent: 4076819 (1978-02-01), Maffrand
patent: 4439606 (1984-03-01), Du et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5614534 (1997-03-01), Binet et al.
patent: 5633247 (1997-05-01), Baldwin et al.
patent: 5668138 (1997-09-01), Baziard-Mouysset et al.
patent: 5852029 (1998-12-01), Fisher et al.
patent: 5981754 (1999-11-01), Badone et al.
patent: 6547958 (2003-04-01), Elomari et al.
patent: 2003/0229119 (2003-12-01), Kym et al.
patent: 2005/0080078 (2005-04-01), Aquila et al.
patent: 2006/0149070 (2006-07-01), Rohde et al.
patent: 2006/0199816 (2006-09-01), Gillespie et al.
patent: 04-334357 (1992-11-01), None
patent: WO 03/053915 (2000-07-01), None
patent: WO 01/05790 (2001-01-01), None
patent: WO 03/037847 (2003-05-01), None
patent: WO 03/049736 (2003-06-01), None
patent: WO 2004/005295 (2004-01-01), None
patent: WO 2004/056745 (2004-07-01), None
patent: WO 2004/065351 (2004-08-01), None
patent: WO 2004/089470 (2004-10-01), None
patent: WO 2004/089896 (2004-10-01), None
patent: WO 2005/037814 (2005-04-01), None
patent: WO 2005/047286 (2005-05-01), None
patent: WO 2005/061499 (2005-07-01), None
patent: WO 2005/108359 (2005-11-01), None
patent: WO 2005/110992 (2005-11-01), None
patent: WO 2006/002349 (2006-01-01), None
patent: WO 2006/002350 (2006-01-01), None
patent: WO 2006/002361 (2006-01-01), None
patent: WO 2006/012173 (2006-02-01), None
patent: WO 2006/012226 (2006-02-01), None
patent: WO 2006/012227 (2006-02-01), None
patent: WO 2006/020598 (2006-02-01), None
patent: WO 2006/053024 (2006-05-01), None
patent: WO 2006/055752 (2006-05-01), None
Grundy, et al., Diagnosis and Management of the Metabolic Syndrome, Circulation, Journal of the American Heart Association, 2005, 112; pp. 2735-2752.
Alberts et al. Endocrinology (2003) 144: 4755-4762.
Albiston et al. (1994) Mol. Cell. Endocrin. 105: R11-R17.
Barf et al. (2002) J. Med. Chem. 45: 3813-3815.
Bellows et al. (1998) Bone 23: 119-125.
Bhargava et al., (2001), Endo 142: 1587-1594.
Billaudel and Sutter (1979) Horm. Metab. Res. 11: 555-560.
Blum, et al., (2003) Prog. Nucl. Acid Res. Mol. Biol. 75:173-216.
Bujalska et al. (1997) Lancet 349: 1210-1213.
Cannalis (1996) J. Clin. Endocrinol. Metab. 81: 3441-3447.
Combs, A. P.; Tadesse, S.; Rafalski, M.; Haque, T. S.; Lam, P. Y. S. J. Comb. Chem. 2002, 4, 179.
Conn, (1955), J. Lab. Clin. Med. 45: 6-17.
Cooper et al. (2000) Bone 27: 375-381.
Database CAPLUS on STN (Columbus, OH, USA) No. 108:131815, Preparation and testing of f7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones as phosphodiesterase and bloodplatelet aggregation inhibitors, abstract, Meanwell, et al. (1988) see RN 113288-90-7.
Database CAPLUS on STN (Columbus, OH, USA) No. 118:255342, {re[artopm pf M-heterpcuc;u;carbpmu;a,omp acids and analogs as prolylendopeptidase inhibitors' abstract, Hosoda et al. (1993) see RN 147635-61-8.
Davani et al. (2000) J. Biol. Chem. 275: 34841-34844.
Draper et al. (2003) Nat. Genet. 34: 434-439.
E. Mishani, et al. Tetrahedron Lett. 1996, 37, 319.
Edwards et al. (1988) Lancet 2: 986-989.
Engeli, et al., (2004) Obes. Res. 12: 9-17.
Funder et al. (1988), Science 242: 583-585.
Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991*.
Jausons-Loffreda et al. J Biolumin and Chemilumin, 1994, 9: 217-221.
Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929.
Kurukulasuriya , et al., (2003) Curr. Med. Chem. 10: 123-53.
Lindsay et al. (2003) J. Clin. Endocrinol. Metab. 88: 2738-2744.
Livingstone et al. (2000) Endocrinology 131: 560-563.
Louie, J; Hartwig, J. F. Tetrahedron Lett. 1995, 36, 3609.
Bolm, C. et al. J. Org. Chem. 2005, 70, 2346.
Low et al. (1994) J. Mol. Endocrin. 13: 167-174.
Lupien et al. (1998) Nat. Neurosci. 1: 69-73.
M. G. Bursavich, D. H. Rich, Org. Lett. 2001, 3, 2625.
Masuzaki et al. (2001) Science 294: 2166-2170.
Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90.
Masuzaki, et al., (2003) Curr. Drug Targets Immune Endocr. Metabol. Disord. 3: 255-62.
Matsuzawa et al. (1999) Ann. N.Y. Acad. Sci. 892: 146-154.
McEwen and Sapolsky (1995) Curr. Opin. Neurobiol. 5: 205-216.
Miller and Chrousos (2001) Endocrinology and Metabolism, eds. Felig and Frohman (McGraw-Hill, New York), 4th Ed.: 387-524.
Morton et al. (2001) J. Biol. Chem. 276: 41293-41300.
Morton et al. (2004) Diabetes 53: 931-938.
Ogawa et al. (1992) J. Clin. Invest. 90: 497-504.
Pitt et al., New England J. Med. (1999), 341: 709-719.
Pitt et al., New England J. Med. (2003), 348: 1309-1321.
Rajan et al. (1996) J. Neurosci. 16: 65-70.
Rask et al. (2001) J. Clin. Endocrinol. Metab. 86: 1418-1421.
Rauz et al. (2001) Invest. Ophthalmol. Vis. Sci. 42: 2037-2042.
Reaven (1993) Ann. Rev. Med. 44: 121-131.
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418.
Journal of Pharmaceutical Science, 66, 2 (1977).
S. M. Dankwardt, et al., Tetrahedron Lett. 1995, 36, 4923.
Stokes et al. (2000) Invest. Ophthamol. Vis. Sci. 41: 1629-1683.
T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987*.
von Geldern, Thomas W. et al. Biorg & Med. Chem. Lett. 2005, 15, 195.
Wajchenberg (2000) Endocr. Rev. 21: 697-738.
Wake et al. (2003) J. Clin. Endocrinol. Metab. 88: 3983-3988.
Walker et al. (1979) Hypertension 1: 287-291.
Wilson et al. (1998) Proc. Natl. Acad. Sci. 95: 10200-10205.
Woolven, James M. et al. J. Med. Chem. 2003, 46, 4428.
Yau et al. (2001) Proc. Natl. Acad. Sci. 98: 4716-4721.

Affiliated with

Also associated with

Rating

Amido compounds and their use as pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amido compounds and their use as pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amido compounds and their use as pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3865269